Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data - Randomization to be Completed in Phase II Part in Q4 2025
information fournie par Boursorama CP 16/09/2025 à 17:45
Ajoutez Boursorama à vos sources préférées

2025 Half-Year Results and Business Update



Positive Phase I data with TG4050 in operable Head and Neck Squamous Cell Carcinoma (HNSCC)


• 100% disease-free survival after 2 years of follow-up — data presented in a rapid oral presentation at ASCO (June 2025)


• Transgene to report additional immunological data at a scientific conference in Q4 2025



Ongoing Phase II part with TG4050 in operable HNSCC


• Patient screening completed, completion of randomization expected in Q4 2025


• First immunogenicity data expected in H2 2026, and efficacy data expected in Q4 2027



Preparing new Phase I trial in an additional indication



Business funded until the end of December 2026


Conference call scheduled today at 6 p.m. CET (in English). See details below


.../...

Valeurs associées

TRANSGENE
0,8280 EUR Euronext Paris -1,43%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
BIOPHYTIS
0,119 -9,85%
HAFFNER ENERGY
0,582 -9,20%
CAC 40
8 473,85 -0,33%
VALNEVA
2,995 +3,28%
Pétrole Brent
93,88 +2,43%
Chargement...

Pages les plus populaires

L'offre BoursoBank